华森制药：关于子公司获得创新药《药物临床试验批准通知书》的公告

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets, marking a significant milestone for the company's innovative drug development [1]. Group 1 - HSN002066C1 tablets are the first Class 1 innovative drug project approved for clinical trials by Huason Inno, highlighting the company's commitment to innovation in drug development [1]. - The approval is expected to lay a solid foundation for the company's strategy of combining innovation and generics in its development approach [1].